TOVX: סך החוב של החברה Theriva Biologics

Theriva Biologics, Inc. (TOVX) minimizes technological threats by developing tools to support microflora and combat neoplasms. The development of viral drugs relies on partnerships with scientific institutes, which increases the likelihood of acquisition by market behemoths. The confirmed price history on this chart reflects the current level of 0.00, while the business funds costly research using existing cash reserves.

The development of VCN-01 immunotherapy requires significant capital expenditures for safety and inhibitor combinations, making the financial stability of Theriva Biologics, Inc. (TOVX) critical. The total volume of loans and bonds, reflected in the company's debt history, allows for an assessment of the balance between leverage and business viability, helping investors determine the risk of default or the potential for growth in shareholder returns.